LORET, Erwann; DARQUE, Albert; JOUVE, Elisabeth; LORET, Elvenn; NICOLINO-BRUNET, Corinne; MORANGE, Sophie; CASTANIER, Elisabeth; CASANOVA, Josiane; CALOUSTIAN, Christine; BORNET, Charleric; COUSSIROU, Julie; BOUSSETTA, Jihen; COUALLIER, Vincent; BLIN, Olivier; DUSSOL, Bertrand; RAVAUX, Isabelle

doi:10.1186/s12977-016-0251-3

Métadonnées

Afficher la notice complète

Licence d’utilisation du document

LORET, Erwann
Institut méditerranéen de biodiversité et d'écologie marine et continentale [IMBE]

DARQUE, Albert
Hôpital de la Conception [CHU - APHM] [LA CONCEPTION]

JOUVE, Elisabeth
Hôpital de la Timone [CHU - APHM] [TIMONE]

Langue

Article de revue

Ce document a été publié dans

Retrovirology. 2016-12, vol. 13, n° 1

BioMed Central

Résumé en anglais

Background: A Tat Oyi vaccine preparation was administered with informed consent to 48 long-term HIV-1 infected volunteers whose viral loads had been suppressed by antiretroviral therapy (cART). These volunteers were rand-omized in double-blind method into four groups (n = 12) that were injected intradermally with 0, 11, 33, or 99 µg of synthetic Tat Oyi proteins in buffer without adjuvant at times designated by month 0 (M0), M1 and M2, respectively. The volunteers then underwent a structured treatment interruption between M5 and M7. Results: The primary outcomes of this phase I/IIa clinical trial were the safety and lowering the extent of HIV RNA rebound after cART interruption. Only one undesirable event possibly due to vaccination was observed. The 33 µg dose was most effective at lowering the extent of HIV RNA and DNA rebound (Mann and Whitney test, p = 0.07 and p = 0.001). Immune responses against Tat were increased at M5 and this correlated with a low HIV RNA rebound at M6 (p = 0.01). Conclusion: This study suggests in vivo that extracellular Tat activates and protects HIV infected cells. The Tat Oyi vaccine in association with cART may provide an efficient means of controlling the HIV-infected cell reservoir.< Réduire

Mots clés en anglais

ART interruption

Vaccine

Clinical trial

Tat

HIV

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial

Langue

Ce document a été publié dans

Résumé en anglais

Mots clés en anglais

URI

DOI

Origine

Unités de recherche